Stockscreener 앱 받기
25.70
2.76%
-0.75
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - Yahoo Finance
Pacira BioSciences soars 52% following InvestingPro’s October Fair Value alert By Investing.com - Investing.com
(PCRX) Trading Advice - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
How did Pacira BioSciences Inc (PCRX) fare last session? - uspostnews.com
Pacira BioSciences (PCRX) to Present Gene Therapy Study Results - GuruFocus
Pacira BioSciences to Present New Data on Clinical Immunogenicit - GuruFocus
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis - GlobeNewswire
Revolutionary Gene Therapy Data: Pacira's New Approach Could Transform Knee Osteoarthritis Treatment - Stock Titan
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $26.67 - Defense World
Are Smart Investors Making the Right Decision? Pacira BioSciences Inc (PCRX) - Sete News
The Potential Rise in the Price of Pacira BioSciences Inc (PCRX) following insiders activity - knoxdaily.com
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for - Nasdaq
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - GlobeNewswire
Leading Pain Management Company Pacira Sets Q1 2025 Earnings Call DateKey Details Inside - Stock Titan
LPL Financial LLC Purchases Shares of 13,321 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences Inc (PCRX) Shares Up 3.97% on Apr 28 - GuruFocus
Pacira releases positive two-year data on knee osteoarthritis candidate - Seeking Alpha
Pacira BioSciences' Gene Therapy Shows Long-Term Improvement in Knee Osteoarthritis Symptoms - marketscreener.com
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee - GlobeNewswire
Invesco Ltd. Cuts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Zacks Research Issues Pessimistic Outlook for PCRX Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Pacira BioSciences Inc (NASDAQ:PCRX)’s 12-Month Price Target Currently Stands At 48 - Marketing Sentinel
Do investors need to be concerned about Pacira BioSciences Inc (PCRX)? - uspostnews.com
Pacira BioSciences Inc [PCRX] Officer makes an insider purchase of 500 shares worth 11625.0. - knoxdaily.com
Investors who hold shares of Pacira BioSciences, Inc. (NASDAQ: - openPR.com
Pacira BioSciences to Present 104-Week Efficacy Data - GlobeNewswire
Revolutionary Gene Therapy Shows 2-Year Effectiveness for Knee Arthritis After Single Dose - Stock Titan
Pacira BioSciences initiates $300M stock buyback - Investing.com
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Pacira BioSciences authorizes $300M share repurchase program - MSN
Pacira BioSciences (PCRX) Enhances Shareholder Value with Capita - GuruFocus
Pacira BioSciences (PCRX) Enhances Shareholder Value with Capital Allocation Strategy - GuruFocus
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization As A Meaningful Step To Enhance Value For Shareholders - marketscreener.com
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders – Company AnnouncementFT.com - Financial Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Bank of Montreal Can - Defense World
Pacira's Largest-Ever $300M Buyback Signals Major Growth PhaseKey Investor Catalyst Revealed - Stock Titan
Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Lifted by Geode Capital Management LLC - Defense World
(PCRX) Investment Analysis and Advice - news.stocktradersdaily.com
Pacira BioSciences initiates $300 million buyback plan By Investing.com - Investing.com India
Pacira Biosciences announces $300M share repurchase program - MSN
Pacira (PCRX) Announces New $300M Share Repurchase Plan | PCRX Stock News - GuruFocus
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Pacira Biosciences IncAuthorizes $300 Million Share Repurchase Program - marketscreener.com
Pacira Biosciences Approves $300M Share Buyback - MarketWatch
Pacira BioSciences initiates $300 million buyback plan - Investing.com
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders | PCRX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect - markets.businessinsider.com
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? - Yahoo Finance
0.92%
0.75%
자본화:
|
볼륨(24시간):